

Conference Highlights:

- Nanomedicine
- Design of Nanodrugs
- Personalized Nanomedicine
- Nanomaterials for drug delivery
- Nanomedicine and Nanotechnology
- Synthesis of Nanoparticles for Drug Delivery
- Drug Delivery Research
- Novel Drug Delivery Systems
- Smart Drug Delivery Technology
- Regenerative Medicine and Tissue Engineering
- Biopharmaceutics and Biologic Drugs
- Nano Pharmaceutical Industry and Market
- Regulatory Aspects Towards Approval of Nanomedicine

2nd International Conference and Exhibition on

Nanomedicine and Drug Delivery Nanodelivery 2018

    @DrugDeliveryCon

May 21-23, 2018
Tokyo, Japan

300+

Participation
(70 Industry: 30 Academia)

10+

Interactive
Sessions

12+

Keynote
Lectures

50+

Plenary
Lectures

3+

Workshops

10+

Exhibitors


B2B

Meetings

Academic Partners



Media Partners



Collaborators



Invitation



Conference Highlights:

- Nanomedicine
- Design of Nanodrugs
- Personalized Nanomedicine
- Nanomaterials for drug delivery
- Nanomedicine and Nanotechnology
- Synthesis of Nanoparticles for Drug Delivery
- Drug Delivery Research
- Novel Drug Delivery Systems
- Smart Drug Delivery Technology
- Regenerative Medicine and Tissue Engineering
- Biopharmaceutics and Biologic Drugs
- Nano Pharmaceutical Industry and Market
- Regulatory Aspects Towards Approval of Nanomedicine

Possessing the right formulation and drug delivery strategy is the foundation of successful drug development. But how do you achieve this? There are on-going innovations in technology, processes and partnership types being trialed across the industry. It's vital to stay abreast of these developments and look to incorporate selected elements into your existing practice to buoy strengths further and overcome weaknesses.

Nanodelivery 2018 provides the perfect platform for just this as an interactive and engaging 3-day event: unique in format, content, networking and engagement. The event brings together truly innovative thinkers who are leading the way through trialing new disruptive solutions and rethinking the conventional formulation and delivery mind-set.

Nanodelivery 2018 will help you to better understand how to develop the right formulation and delivery strategy with a strong scientific, clinical and commercial mind set and how innovative scientific techniques, emerging technologies and innovative devices can transform formulation and drug delivery.

Regards,
Nanodelivery 2018 Organizing Committee



Hiroshi Maeda
Osaka University Medical School, Japan



Haruo Sugi
Teikyo University Japan



Prasad Kanteti
University of Illinois USA



Shaoqin Sarah Gong
University of Wisconsin-Madison, USA



Abraham J Domb
Hebrew University of Jerusalem, Israel



Kenji Suzuki
Illinois Institute of Technology, USA



Veronique Preat
Catholic University of Louvain, Belgium

Academic Partners



Summary of Nano Delivery 2018 Conference:

Nano Delivery 2018 is an emerging field of engineering and life sciences that promises to revolutionize medicine and medical technology. There are numerous applications of nanomedicine and nanotechnology in medicinal diagnostics. These include improved imagining of the human (or any) body and detecting tumors that are only a few cells in size.

The idea that pharmaceutical agents should be delivered specifically to diseased cells holds the promise of a variety of benefits. The promise of individualized medicine is that it is efficient. Targeted drug-delivery allows doctors and patients to benefit from small dosages at just the right place and thus from fewer side effects.

Nanomedicine has therapeutic uses as well. Nanotechnology is capable of delivering medication to the exact location where they are needed, hence lesser side effects. It can also be used to destroy harmful organisms or cancer cells by interrupting their division process. Nanoprobes can be made to generate radiation that could kill bacteria, viruses and cancer cells. Nanotechnology also theoretically allows the mimicking of natural biological processes, e.g. repair of damaged tissues or acting as artificial red blood cells to transport oxygen.

The global market for healthcare nanotechnology is expected to reach USD 196.02 billion by 2020 growing at a CAGR of 12.1%, according to a new study by Grand View Research, Inc. Increasing susceptibility of patients towards chronic diseases such as cardiovascular, neurological, oncology and respiratory diseases coupled with increasing R&D spending opening new application avenues is expected to drive market growth over the next six years. Other drivers of this market include increasing government and private sector R&D aid and new players entering the market to bridge the gap between supply and demand.

Importance & Scope of Nano Delivery:

Researchers are developing a nanoparticle that can be taken orally and pass through the lining of the intestines into the bloodstream. This should allow drugs that must now be delivered with a shot to be taken in pill form. The researchers have demonstrated the technique with lab mice so far.

Researchers are also developing a nanoparticle to defeat viruses. The nanoparticle does not actually destroy viruses molecules, but delivers an enzyme that prevents the reproduction of viruses molecules in the patients bloodstream. The effectiveness of the technique has been demonstrated in lab tests.


Nanomedicine Market in Japan:Why Japan?

Nanomedicine is a promising sub-segment in medicine that took off in the 1980s with the first generation of developed nanopharmaceuticals. With the use of nanotechnology, drugs can be delivered in ways not experienced so far. U.S. is a strong actor in this field with many patents having commercialized several nanopharmaceuticals.

The global nanomedicine market was valued at US\$50.1 billion in 2011 and is projected to grow to US\$96.9 billion in 2016. The share of nanomedicine to the total global pharmaceutical market is estimated at 5.3 percent in 2011 indicating its niche character presently.

In Japan, for various reasons, the nanomedicine market size in terms of the total market is much smaller. A rough estimate shows that the share is between 1 to 2 percent corresponding to approximately US\$1 to 2 billion. A limited number of approved Japanese nanodrugs together with a long time until approved foreign products entered the Japanese market have seemingly slowed the market expansion.

- Japan = World's 2nd largest pharmaceutical market!
- Japan is the 2nd largest pharmaceutical market in the world, marking JPY 10 trillion (USD 84.4 billion) in ethical drug in 2016.
- Nikkei Stock Average has been continuously increasing since mid October, 2016.
- The government is to ease the regulations to develop new medicines for intractable diseases by shortening 5 years of drug development time.
- Japan hugely depends on imported pharmaceutical products. The annual import value in Japan was JPY 1.94 trillion (USD 16 billion) in 2015 compared to the export value of JPY 0.32 trillion (USD 2.7 billion).



Japan's pharmaceutical industry is the world's second largest market, after U.S., valued at US\$112.1 billion in 2012 or 11.6 percent of the world market. Historically, the market has been protected from foreign competition. These days, however, deregulation has prompted investment from abroad and increased the presence of foreign companies. The pharmaceutical industry is one of the few industrial sectors in which Japan has a trade deficit. Japan imports more than two times what it exports. The rapid aging of the population and the weak global competitiveness of domestic companies are contributing factors to the trade deficit.

Japan Nanomedicine Market Size:

There is no market information available on the size of Japan's nanomedicine market published by any of the large Japanese market research companies. Table 2 below tries to estimate the market size. The global nanomedicine market was estimated to be about 5 percent of the global pharmaceutical market in 2010 and 2011. In case of Japan, this ratio is much lower compared to the global nanomedicine market. A rough estimate indicates that the market size was approximately 1-2 percent of the Japanese pharmaceutical market in 2011-2012, or roughly between US\$1 billion – US\$2 billion. The drug lag of imported nanopharmaceuticals (explained in section 3.5.) is one cause of this. Nanomedicines have not been defined in Japan and are regulated within the general framework of the Pharmaceutical Affairs Law (PAL) on a product-by-product basis (20).

Approved Nanopharmaceutical Products by Application:

As there is no specific definition for drug and device (nanocarrier) combinations, they are regulated as drugs or medical devices according to their main function or purpose (20).

Pharmaceuticals are classified as nanomedicine by their sizes, i.e. materials in the submicron range. Information on marketed nanopharmaceuticals in Japan comes from various sources (21) including “Current Initiatives in Japan for Nanomedicines”, Kumiko Sakai-Kato, Toru Kawanishi, 2011, National Institute of Health Sciences (NIHS) and Ministry of Health, Labour and Welfare (MHLW) (22).

Trade name	Technology	Compound	Company
Ropion	Lipid emulsion	Flurbiprofen	Kaken (JPN)
Visudyne	Liposome	Verteporfin	Novartis
Zevalin	Antibody Conjugates	Zevalin	Bayer
Somavert	PEGylated protein	Pegvisomant	Pfizer
Emend	Nanocrystal	Aprepitant	Merck
Abraxane	Polymeric Nanoparticles	Paclitaxel	Abraxis

Government Pushing for Change:

In order to reduce the time span from discovery and innovation to commercialization, the importance to establish open user facility networks to promote the integration of dissimilar fields and academic-industry collaboration is emphasized.

It is apparent that the government is aiming at more concrete and speedy results for R&D. Issue-driven innovation based on “exit-oriented” R&D is targeted to impact the competitive power of related industries.

A report by the Japan Science & Technology Agency titled “Japan’s New Science and Innovation Policy – Beyond the Boundaries for Innovation”, published in 2016 (50) lists up the time span for selected target applications of nanomedicine, such as:

- Molecular imaging (2015-2020)
- Integrated system of drug delivery, diagnosis and treatment (2015-2020)
- Implant devices for diagnosis and treatment (2020-2030)
- Nano-cell surgery (2020-2030)
- 3D-imaging in cells (2020-2030)

These are quite ambitious targets showing the directions where R&D will be focused.

In addition to the latest basic plan, there are other signals that the government is increasingly prioritizing innovative medicine. For instance, The Ministry of Health, Labour and Welfare will jointly with the European Union (EU) promote the development of nano-based block copolymer micelles. Together with European Medicines Agency (EMA) the ministry has released a reflection paper (February 2013) emphasizing that such micelles are able to preferentially accumulate in solid tumors (51).

Nanomedicine – Research and Development in Japan:

- University of Tokyo
- Hokkaido University
- Tokyo Prefecture University
- Tokyo University
- Tohoku University
- National Institute for Materials Science

The Japanese Nanomedicine Industry:

Nanomedicine start-ups and small-medium enterprises have driven the innovation process, not only in US and Europe but also in Japan. The commercialization of nanopharmaceuticals have basically followed three types of business models (67), such as:

- Development of a nanotechnology platform used to add value to second-party products
- Development and manufacturing of high-value materials for the pharmaceutical industry
- Development of nanotechnology-improved pharmaceuticals or medical devices

The majority of start-ups has adopted the third business model utilizing nanotechnology to develop own proprietary product pipelines. Often such companies introduce new or standard drugs that are delivered with a drug delivery system. Then they try to team up with pharmaceutical companies that take the products through the clinical trials.

- NanoCarrier Co., Ltd.
- LTT Bio-Pharma Co., Ltd.
- Mebiopharm Co., Ltd.
- Nippon Kayaku Co., Ltd
- Kowa Company Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Taisho Pharmaceutical Co., Ltd.
- Astellas Pharma Inc
- Kaken Pharmaceutical Co., Ltd.

Target Audience:

- Pharmaceutical Scientists
- Drug Delivery Researchers
- Nanomedicine Scientists
- Medicine clinicians
- Pharmacists
- Molecular Scientists
- Pharmaceutical Associations and Societies
- Pharmaceutical Faculty
- Medical Colleges

- Data Management Companies
- Training Institutes
- Software developing companies
- Business Entrepreneurs and Many More....

Global Nanotechnology Drug Delivery Market, by Technology:

- Nanocrystals
- Nanoparticles
- Dendrimers
- Gold Nanopartilces
- Dendrimers
- Fullerenes
- Others
- Liposomes
- Micelles
- Nanotubes
- Others

Pharmaceutical Regulations in Japan:

Manufacturing, importation, and sales of drugs and medical devices are regulated by the Pharmaceutical Affairs Law (PAL) of Japan.

All manufacturing and marketing applications in Japan for drugs and devices are reviewed by the Pharmaceutical and Medical Devices Agency (PMDA) (83). All applications are thoroughly reviewed before PMDA submits an approval recommendation to the Ministry of Health, Labour and Welfare (MHLW).

Under PAL, when importing to Japan and selling pharmaceutical products manufactured in other countries, a license for marketing authorization is required. The Marketing Authorization Holder (MAH) will be the owner of the license for marketing authorization.

The MAH must be based in Japan and can be the foreign company's Japan office, the foreign company's distributor, or an independent third party acting as the Designated Marketing Authorization Holder (DMAH).


To import and market a new drug in Japan, an approval (marketing approval) will be necessary. And the approval must be held by the Marketing Authorization Holder.

A foreign manufacturer intending to manufacture drugs in foreign countries and export them to Japan, is required to be accredited by MHLW as an "Accredited Foreign Manufacturer" (84). And it is necessary to obtain accreditation for each foreign factory location at which pharmaceuticals for export are manufactured.

The appointed MAH will be responsible for the labelling and advertising of the pharmaceuticals in Japan. As stipulated in PAL, the manufacturers/seller's address, name of product, production indication, name of ingredients, expiration, etc., must be printed on the container of drugs.

Overall research in various disciplines:

The North American nanomedicine market held the majority of global market share in 2012 because of the rapidly growing nanomedicine market in the Asia-Pacific, Latin American and African region, presence of large number of patented nanomedicine products and favorable regulatory framework in the region. In addition, the presence of sophisticated healthcare infrastructure supports development of advanced products such as nano probes, nanorobots, monoclonal antibody based immunoassays and nanoparticle based imaging agents for early detection of diseases.



However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as China, India and other economies in the region. China is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region.

Major Nano Delivery Associations around the Globe:

- American Nano Society
- European Biotechnology Thematic Network Association
- Society for Biomaterials
- Nano Canadian Society
- American Academy of NanoMedicine
- American Association for the Advancement of Science
- Nanometer-Scale Science and Technology Division of the American Vacuum Society
- NanoScience and Technology Institute
- ASME NanoTechnology Institute
- Foresight Nanotech Institute
- International Association of NanoTechnology
- The Institute of NanoTechnology
- Microscopy Society of America
- Nano Business Alliance
- European NanoTechnology Gateway
- Scottish Center for NanoTechnology in Construction Materials
- Royal Society-NanoTechnology and NanoScience
- Czech NanoTechnology Industries Association
- Erwin Schrodinger Society for NanoSciences
- Innovationsallianz Carbon NanoTubes
- NanoTechnologies for Tommorow's Society
- American Association for the Advancement of Science

Companies involved in Nano Delivery:

USA

Oncolytics Biotech
Bristol-Myers Squibb
GlaxoSmithKline
Bend Research
Pfizer
BioDelivery Sciences
GE Healthcare
Mallinckrodt plc
Nanosphere Inc., USA
Pfizer Inc., USA

Merck & Co Inc., USA
Celgene Corporation, USA
CombiMatrix Corporation, USA
Abbott Laboratories

Many Major companies in the Nano Delivery market.

Global

PolyActivaUnilife
Mati Therapeutics
Formac Pharmaceuticals
Battelle

Toxikon
Novartis
Johnson & Johnson
Merck & Co
Novartis International AG
Pfizer
Roche
Bayer AG
AbbVie
Amgen
Celgene Corporation



Conference Highlights:

Tentative Agenda

Nanomedicine
Design of Nanodrugs
Personalized Nanomedicine
Nanomaterials for drug delivery
Nanomedicine and Nanotechnology
Synthesis of Nanoparticles for Drug Delivery
Drug Delivery Research
Novel Drug Delivery Systems
Smart Drug Delivery Technology
Regenerative Medicine and Tissue Engineering
Biopharmaceutics and Biologic Drugs
Nano Pharmaceutical Industry and Market
Regulatory Aspects Towards Approval of Nanomedicine

Academic Partners



May 21, 2018 Monday

Time	Session
08:30-09:30	Registrations
09:30-11:30	Keynote Forum
Group Photo	
11:30-11:45	Network & Refreshments Break*
11:45-13:00	Track 1: Nanomedicine
	Track 2: Design of Nanodrugs
13:00-13:45	Lunch Break**
13:45-16:00	Track 3: Personalized Nanomedicine
16:00-16:15	Network & Refreshments Break*
16:15-18:00	Track 4: Nanomaterials for drug delivery
Day Concludes	

May 23, 2018 Wednesday

Time	Session
09:30-11:30	Track 9: Regenerative Medicine and Tissue Engineering
11:30-11:45	Network & Refreshments Break*
11:45-13:00	Track 10: Nano Pharmaceuticals
13:00-13:45	Lunch Break**
13:45-16:00	Track 11: Nano Pharmaceutical Industry and Market
16:00-16:15	Network & Refreshments Break*
16:15-18:00	Track 12: Regulatory Aspects Towards Approval of Nanomedicine
Award Ceremony	
Conference Concludes	

Call for Abstract : <https://nanomedicine.pharmaceuticalconferences.com/call-for-abstracts.php>

Registration : <https://nanomedicine.pharmaceuticalconferences.com/registration.php>

Abstract Submission : <https://nanomedicine.pharmaceuticalconferences.com/abstract-submission.php>

May 22, 2018 Tuesday

Time	Session
08:30-09:30	Registrations
09:30-10:30	Keynote Forum
10:30-11:30	Track 5: Nanomedicine and Nanotechnology
11:30-11:45	Network & Refreshments Break*
11:45-13:00	Track 6: Synthesis of Nanoparticles for Drug Delivery
13:00-13:45	Lunch Break**
13:45-16:00	Track 7: Drug Delivery Research
16:00-16:15	Network & Refreshments Break*
16:15-18:00	Track 8: Novel Drug Delivery Systems
16:00-18:00	Poster Presentations
Day Concludes	

* Exclusive Exhibitor Event

** Networking Event

Note: Conference schedule is subject to change.

Note: Workshops and Symposia slots are available. To book slot for Workshop and Symposium send us the proposal.

Conference Highlights:

- Nanomedicine
- Design of Nanodrugs
- Personalized Nanomedicine
- Nanomaterials for drug delivery
- Nanomedicine and Nanotechnology
- Synthesis of Nanoparticles for Drug Delivery
- Drug Delivery Research
- Novel Drug Delivery Systems
- Smart Drug Delivery Technology
- Regenerative Medicine and Tissue Engineering
- Biopharmaceutics and Biologic Drugs
- Nano Pharmaceutical Industry and Market
- Regulatory Aspects Towards Approval of Nanomedicine

Academic Partners



Keynote Speakers



Challenges and Innovations in Nanomedicine and Drug Delivery Research

Hiroshi Maeda
 Osaka University Medical School
 Japan



PED4 inhibitor-loaded phosphatosomes for attenuating neutrophilic inflammation in acute lung injury

Jia-You Fang
 Chang Gung University
 Taiwan



Unimolecular Nanoparticles for Targeted Drug Delivery

Shaoqin Sarah Gong
 University of Wisconsin-Madison
 USA



Nanomedicines for Glioblastoma Treatment

Veronique Preat
 Catholic University of Louvain
 Belgium



Nanocellulose alginate composite for 3D cell growth

Julian Brass
 University Grenoble Alpes,
 France



New biocompatible oxide nanoparticles as carriers of bioactive compounds through the blood-brain barrier

Michał M.
 WULS-SGGW,
 Poland



Conference Highlights:

Nanomedicine
Design of Nanodrugs
Personalized Nanomedicine
Nanomaterials for drug delivery
Nanomedicine and Nanotechnology
Synthesis of Nanoparticles for Drug Delivery
Drug Delivery Research
Novel Drug Delivery Systems
Smart Drug Delivery Technology
Regenerative Medicine and Tissue Engineering
Biopharmaceutics and Biologic Drugs
Nano Pharmaceutical Industry and Market
Regulatory Aspects Towards Approval of Nanomedicine

Poster Presentation

Present Your Research Poster at Our Conference

Benefits:

- Will be published in our conference proceedings and also the conference book.
- Publication of entire article at 50% rebate in the respective subject journals.
- Posters will be evaluated by our Jury and the best poster will be awarded a certificate.

Poster Specifications:

- Present numerical data in the form of graphs, rather than tables (graphs make trends in the data much more evident). If data must be presented in table-form, keep it Simple.

- Visuals should be simple and bold.
- Organize your poster into subdivisions, e.g., Introduction, Methods, Results; Discussion, Conclusions, and Literature Cited (avoid using too many citations).
- Use bright colours to enhance the detail.
- Text should be readable from five feet distance.
- Besides your project, the text could also include future research plans or questions.
- Each poster should be approximately 1x1 M long.
- The title, contents and the author's information should be clearly visible from a distance of 1-2 feet.
- Benefits: Each abstract will be labelled with a Digital Object Identification Number (DOI) provided by Cross Ref
- Abstract pages created in Google on your name would get worldwide acknowledgment to your research.

For more info, PS: <https://nanomedicine.pharmaceuticalconferences.com/poster-presentation.php>

Academic Partners



Conference Highlights:

- Nanomedicine
- Design of Nanodrugs
- Personalized Nanomedicine
- Nanomaterials for drug delivery
- Nanomedicine and Nanotechnology
- Synthesis of Nanoparticles for Drug Delivery
- Drug Delivery Research
- Novel Drug Delivery Systems
- Smart Drug Delivery Technology
- Regenerative Medicine and Tissue Engineering
- Biopharmaceutics and Biologic Drugs
- Nano Pharmaceutical Industry and Market
- Regulatory Aspects Towards Approval of Nanomedicine

Young Researchers Forum

Come Let's Bring a Transformation in the Scientific Society:

The Young Researchers Forum offers young researchers the possibility to meet and discuss research topics and methodologies, share and develop ideas, learn from each other and gain knowledge from senior researchers.

Benefits:

- Showcase your research through oral presentations.
- Learn about career development and the latest research tools and technologies in your field.
- This forum will give pertinent and timely information to those who conduct research and those who use and benefit from research.


- Develop a foundation for collaboration among young researchers.
- The forum will provide an opportunity for collegial interaction with other young investigators and established senior investigators across the globe.
- Interact and share ideas with both peers and mentors.
- Opportunity for young researchers to learn about the research areas of their peers to increase their capacity as multidisciplinary researchers.
- Actively distribute information and promote the benefits of education and career matters.

For more info, PS: <https://nanomedicine.pharmaceuticalconferences.com/young-researchers-forum.php>

Important Dates

- Abstract submission opens: June 19 , 2017**
- Registration opens: June 19 , 2017**
- Early Bird Registration: January 25, 2018**
- Mid Registration: February 27 ,2018**
- On spot registration: May 21 ,2018**

Academic Partners



Conference Highlights:

Nanomedicine

Design of Nanodrugs

Personalized Nanomedicine

Nanomaterials for drug delivery

Nanomedicine and Nanotechnology

Synthesis of Nanoparticles for Drug Delivery

Drug Delivery Research

Novel Drug Delivery Systems

Smart Drug Delivery Technology

Regenerative Medicine and Tissue Engineering

Biopharmaceutics and Biologic Drugs

Nano Pharmaceutical Industry and Market

Regulatory Aspects Towards Approval of Nanomedicine

Venue Details:

HILTON TOKYO NARITA

56 Kosuge, Narita, Chiba Prefecture

286-0127, Tokyo, Japan

For more information visit:

<https://nanomedicine.pharmaceuticalconferences.com/>

Book your Accommodation before
the 27th of February 2018

avail a **\$200**
waiver on the package.

CONTACT

Riley Matthews | Program Director | Nanodelivery 2018

One Commerce Center-1201, Orange St. #600, Wilmington, Delaware, USA

Toll Free: Japan -81-345780247, Singapore -800-852-6126, USA/Canada -1-800-216-6499 and

UK -0-800-098-8455

<mailto:nanodelivery@pharmaceuticalconferences.org> | riley.matthews0677@gmail.com

Tel: +1-702-508-5200 Ext: 6094

Customer Service: +1 (800) 216 6499

For Reservations please contact above or

visit: <https://nanomedicine.pharmaceuticalconferences.com/>

SPONSORSHIP OPPORTUNITIES

HOTEL INFORMATION

REGISTRATION & PRICING

Conference Highlights:

- Nanomedicine
- Design of Nanodrugs
- Personalized Nanomedicine
- Nanomaterials for drug delivery
- Nanomedicine and Nanotechnology
- Synthesis of Nanoparticles for Drug Delivery
- Drug Delivery Research
- Novel Drug Delivery Systems
- Smart Drug Delivery Technology
- Regenerative Medicine and Tissue Engineering
- Biopharmaceutics and Biologic Drugs
- Nano Pharmaceutical Industry and Market
- Regulatory Aspects Towards Approval of Nanomedicine

Exhibitions & Sponsorship Opportunities

Elite Sponsor

\$ 10,000

Gold Sponsor

\$ 7,500

Silver Sponsor

\$ 5,000

Exhibition

\$ 2,500



SPONSORSHIP OPPORTUNITIES

HOTEL INFORMATION

REGISTRATION & PRICING